Genenta Science is developing a cell-based platform that utilizes hematopoietic stem cells to deliver interferon-alpha directly to solid tumors, minimizing systemic toxicity and overcoming tumor-induced immune tolerance. Their lead product, Temferon™, is designed as a one-time therapy that can enhance the effectiveness of existing cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors create an immunosuppressive microenvironment, limiting the effectiveness of traditional cancer treatments. Systemic delivery of immunomodulatory agents often results in significant toxicity, hindering the ability to achieve therapeutic doses within the tumor. Overcoming tumor-induced immune tolerance remains a significant challenge in oncology.
Solution
Genenta Science is developing a cell-based platform to deliver targeted immunotherapies directly to solid tumors, minimizing systemic toxicity and maximizing local efficacy. The platform utilizes hematopoietic stem cells engineered to express therapeutic payloads within the tumor microenvironment. Their lead product, Temferon™, is designed to deliver interferon-alpha specifically to tumor-infiltrating monocytes (TEMs), promoting an anti-tumor immune response. This approach aims to break tumor-induced immune tolerance and enhance the effectiveness of existing cancer treatments. The platform is designed to be tumor-type agnostic, addressing a wide range of solid cancers characterized by the presence of TEMs.
Target Audience
The primary target audience includes patients with solid tumors and significant unmet needs, as well as clinicians seeking to improve treatment outcomes through targeted immunotherapies.
Features
- Cell-based delivery of interferon-alpha directly to the tumor microenvironment using engineered hematopoietic stem cells.
- Targeted expression of therapeutic payloads by tumor-infiltrating monocytes (TEMs).
- Minimized systemic toxicity through localized delivery of immunomodulatory agents.
- Potential for combination therapy to enhance the efficacy of other approved therapeutics.
- Applicability across various solid tumor types characterized by the presence of intratumoral TEMs.
- Utilizes a lentiviral vector for ex-vivo cell transfer strategy.